News

Article

Pfizer Picks Catalent to Manufacture Newly Launched Pain-Relief Product

Pfizer’s new format of ibuprofen (AdvilR Liqui-GelsR Minis) uses Catalent’s softgel technology to deliver the formulation in a more concentrated fill, resulting in smaller capsules.

Catalent Pharma Solutions, provider of advanced drug-delivery technologies, announced that it has entered into an exclusive long-term supply agreement to produce Pfizer’s newly launched over-the-counter (OTC) pain relief product-Advil Liqui-Gels Minis (ibuprofen)-which uses Catalent’s softgel platform OptiGel Mini technology.

Catalent has collaborated with Pfizer for 20 years on the development and manufacture of Advil Liqui-Gels. The new format, Advil Liqui-Gels Minis, delivers the formulation in a more concentrated fill, resulting in smaller capsules that are easier to swallow. Smaller capsules address the problem of swallowing difficulties often experienced by pediatric and geriatric consumers.

Under the arrangement, Catalent’s St. Petersburg, Florida, facility has already formulated and is manufacturing the new format for Pfizer. The new product was recently launched in the US market.

Source: Catalent

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content